cholest-8(14)-en-3-ol-15-one: structure given in first source; regulator of cholesterol metabolism; RN given refers to (3beta,5alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
3beta-hydroxy-5alpha-cholest-8(14)-en-15-one : A 3beta-hydroxysteroid consisting of 3beta-hydroxy-5alpha-cholest-8(14)-ene having an additional oxo group at the 15-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 10046567 |
| CHEMBL ID | 2104586 |
| CHEBI ID | 61829 |
| SCHEMBL ID | 49496 |
| MeSH ID | M0064083 |
| Synonym |
|---|
| 50673-97-7 |
| D03583 |
| colestolone (usan/inn) |
| SMP2_000324 |
| cholest-8(14)-en-15-one, 3-hydroxy-, (3beta,5alpha)- |
| cholest-8(14)-en-3-ol-15-one |
| colestolona [inn-spanish] |
| cl 274,471 |
| colestolone |
| colestolonum [inn-latin] |
| 3beta-hydroxy-5alpha-cholest-8(14)-en-15-one |
| colestolone [usan:inn] |
| LINVVMHRTUSXHL-GGVPDPBRSA-N |
| 3beta-hydroxy-5alpha-cholest-8(14)-ene-15-one |
| (3beta,5alpha)-3-hydroxycholest-8(14)en-15-one |
| 15-ketocholestene |
| 15-oxo-5alpha-cholest-8(14)-en-3beta-ol |
| colestolona |
| colestolonum |
| (3beta,5alpha)-3-hydroxycholest-8(14)-en-15-one |
| CHEBI:61829 , |
| 5alpha-cholest-8(14)-en-3-beta-ol-15-one |
| LMST01010269 |
| tox21_111880 |
| dtxsid6046212 , |
| dtxcid4026212 |
| cas-50673-97-7 |
| cl-274471 |
| CHEMBL2104586 |
| 5p8396t5xf , |
| unii-5p8396t5xf |
| EPITOPE ID:153526 |
| cholest-8(14)-en-15-one, 3-hydroxy-, (3.beta.,5.alpha.)- |
| colestolone [inn] |
| colestolone [usan] |
| SCHEMBL49496 |
| 3b-hydroxy-5a-cholest-8(14)-en-15-one |
| (3s,5s,9r,10s,13r,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,5,6,7,9,11,12,16,17-dodecahydrocyclopenta[a]phenanthren-15-one |
| Q27131432 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| 3beta-hydroxy steroid | A 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position. |
| 15-oxo steroid | Any oxo steroid where the oxo group is located at the 15-position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 29.8554 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.6822 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 29.8493 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 7.4334 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID83166 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 0.0 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| AID83288 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 2.5 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| AID83286 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 0.5 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| AID83287 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 1.0 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| AID83285 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 0.25 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| AID83167 | % control of HMG-CoA reductase activity in CHO-K1 cells at a concentration of 0.1 uM | 1992 | Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4 | Inhibitors of sterol synthesis. 3 beta,25-dihydroxy-5 alpha-cholest-8(14)-en-15-one, an active metabolite of 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 28 (62.22) | 18.7374 |
| 1990's | 12 (26.67) | 18.2507 |
| 2000's | 1 (2.22) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 46 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||